Sound Pharma Announces Phase 3 Study Completion of SPI-1005 for the Treatment of Meniere’s Disease
SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that the Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory, for the treatment of Meniere’s Disease (STOPMD-3) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback